Published in Br J Psychiatry on May 24, 2012
Machine learning approaches for integrating clinical and imaging features in late-life depression classification and response prediction. Int J Geriatr Psychiatry (2015) 0.83
Cerebral Small Vessel Disease and Association With Higher Incidence of Depressive Symptoms in a General Elderly Population: The AGES-Reykjavik Study. Am J Psychiatry (2015) 0.82
White Matter Hyperintensity Accumulation During Treatment of Late-Life Depression. Neuropsychopharmacology (2015) 0.80
Longitudinal change of small-vessel disease-related brain abnormalities. J Cereb Blood Flow Metab (2016) 0.80
Depression in the elderly: clinical features and risk factors. Aging Dis (2012) 0.78
Relationships between Personality Traits, Medial Temporal Lobe Atrophy, and White Matter Lesion in Subjects Suffering from Mild Cognitive Impairment. Front Aging Neurosci (2014) 0.78
MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. Front Aging Neurosci (2017) 0.78
Depressive symptoms related to low fractional anisotropy of white matter underlying the right ventral anterior cingulate in older adults with atherosclerotic vascular disease. Front Hum Neurosci (2015) 0.77
The reduction of regional cerebral blood flow in normal-appearing white matter is associated with the severity of white matter lesions in elderly: a Xeon-CT study. PLoS One (2014) 0.77
Assessing the role of cerebrovascular disease in the incidence of geriatric depression. Br J Psychiatry (2012) 0.75
Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the "Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment" (TRACE-VCI) Study. JMIR Res Protoc (2017) 0.75
Organic bases of late-life depression: a critical update. J Neural Transm (Vienna) (2013) 0.75
Vascular depression consensus report - a critical update. BMC Med (2016) 0.75
Brain structural connectivity in late-life major depressive disorder. Biol Psychiatry Cogn Neurosci Neuroimaging (2016) 0.75
Multimodal imaging findings in normal-appearing white matter of leucoaraiosis: a review. Stroke Vasc Neurol (2016) 0.75
Differential Roles of Environmental Enrichment in Alzheimer's Type of Neurodegeneration and Physiological Aging. Front Aging Neurosci (2017) 0.75
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet (2015) 7.16
National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke (2006) 6.94
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
Comprehensive geriatric assessment for older adults admitted to hospital: meta-analysis of randomised controlled trials. BMJ (2011) 4.34
Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem (2004) 4.23
Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med (2007) 4.11
Effects of augmented exercise therapy time after stroke: a meta-analysis. Stroke (2004) 3.83
Vascular cognitive impairment. Lancet Neurol (2003) 3.73
Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev (2011) 3.71
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
Subcortical ischaemic vascular dementia. Lancet Neurol (2002) 3.32
White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke (2006) 3.27
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. Stroke (2003) 3.15
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
Comprehensive geriatric assessment for older hospital patients. Br Med Bull (2005) 2.64
Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke (2005) 2.59
Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke (2008) 2.57
Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging (2008) 2.51
Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry (2010) 2.44
Profile of cognitive impairment in chronic heart failure. J Am Geriatr Soc (2007) 2.43
European Stroke Initiative Recommendations for Stroke Management-update 2003. Cerebrovasc Dis (2003) 2.35
Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem (2009) 2.32
Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke (2003) 2.31
Carotid artery stenting: first consensus document of the ICCS-SPREAD Joint Committee. Stroke (2006) 2.21
Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol (2006) 2.16
Risk factors in late adolescence for young-onset dementia in men: a nationwide cohort study. JAMA Intern Med (2013) 2.15
Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol (2005) 2.10
Do white matter hyperintensities on MRI matter clinically? BMJ (2010) 2.07
Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain (2004) 2.06
[Cognitive medicine--field of knowledge for future specialist education]. Lakartidningen (2008) 2.03
Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology (2004) 2.00
Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord (2013) 1.98
Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry (2002) 1.96
Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther (2006) 1.96
Impact of age-related cerebral white matter changes on the transition to disability -- the LADIS study: rationale, design and methodology. Neuroepidemiology (2005) 1.92
Ischemic basis for deep white matter hyperintensities in major depression: a neuropathological study. Arch Gen Psychiatry (2002) 1.88
Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke (2006) 1.88
Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis (2010) 1.86
Occupational therapy for patients with problems in personal activities of daily living after stroke: systematic review of randomised trials. BMJ (2007) 1.85
Brain microbleeds and Alzheimer's disease: innocent observation or key player? Brain (2011) 1.82
Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies. Am J Psychiatry (2004) 1.82
Uncovering treatment burden as a key concept for stroke care: a systematic review of qualitative research. PLoS Med (2013) 1.79
Shining a light on posterior cortical atrophy. Alzheimers Dement (2012) 1.77
Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med (2009) 1.77
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. Stroke (2008) 1.75
A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry (2004) 1.74
Barthel index for stroke trials: development, properties, and application. Stroke (2011) 1.68
Early discharge hospital at home. Cochrane Database Syst Rev (2009) 1.67
Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging (2008) 1.67
Noninvasive cardiac event monitoring to detect atrial fibrillation after ischemic stroke: a randomized, controlled trial. Stroke (2013) 1.66
Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology (2012) 1.62
Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease? Mov Disord (2013) 1.61
Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging (2007) 1.61
D-dimer predicts early clinical progression in ischemic stroke: confirmation using routine clinical assays. Stroke (2006) 1.60
Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett (2008) 1.60
Visual hallucinations in dementia with Lewy bodies: transcranial magnetic stimulation study. Br J Psychiatry (2011) 1.58
Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke (2009) 1.57
Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. J Alzheimers Dis (2012) 1.57
Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology (2008) 1.56
Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging (2002) 1.56
Early-versus late-onset Alzheimer's disease: more than age alone. J Alzheimers Dis (2010) 1.54
Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2011) 1.54
Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. BMC Neurosci (2009) 1.54
Diffusion changes predict cognitive and functional outcome: the LADIS study. Ann Neurol (2013) 1.54